(2R,3R)-5-(benzyloxy)-2-octylpentane-1,3-diol | 1204612-24-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (2R,3R)-5-(benzyloxy)-2-octylpentane-1,3-diol
• 英文别名: (2R,3R)-2-octyl-5-phenylmethoxypentane-1,3-diol
• CAS: 1204612-24-7
• 化学式: C₂₀H₃₄O₃
• 分子量: 322.488
• InChiKey: QRMOODFJQAFZPW-WOJBJXKFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  23
• 可旋转键数：
  14
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  49.7
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (2R,3R)-5-(benzyloxy)-2-octylpentane-1,3-diol 、 2,2-二甲氧基丙烷 在 对甲苯磺酸 作用下， 以 二氯甲烷 为溶剂， 反应 4.0h， 生成 (4R,5R)-4-(2-(benzyloxy)ethyl)-2,2-dimethyl-5-octyl-1,3-dioxane
  参考文献：
  名称：

  Inhibition of IkB kinase and NF-κB by a novel synthetic compound SK 2009

  摘要：

  The NF-kappa B family of transcription factors plays an important role in determining cell survival during immune, inflammatory, and stress responses. NF-kappa B activity is frequently deregulated in human cancers and is implicated in the resistance of tumor cells to diverse anticancer agents. We studied the effects of novel analogs of precursors of the natural product simplactone (A) on the activity of IkB kinase and NF-kappa B. Screening of six compounds for the ability to inhibit TNF-induced NF-kappa B activity revealed that compound SK2009 was the most potent of these compounds in suppressing NF-kappa B activation in KBM-5 leukemic cells. Further characterization of SK2009 indicates that this newly synthesized molecule can suppress TNF-induced I kappa B alpha kinase activation and inhibit the expression of three NF-kappa B-dependent gene products, cyclin D1, Bcl-2, and VEGF, in these cells. Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmc.2009.10.065
• 作为产物：
  描述：

  (S)-3-((S)-2-((R)-3-(benzyloxy)-1-hydroxypropyl)decanoyl)-4-benzyloxazolidin-2-one 在 sodium tetrahydroborate 、 水 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 生成 (2R,3R)-5-(benzyloxy)-2-octylpentane-1,3-diol
  参考文献：
  名称：

  Inhibition of IkB kinase and NF-κB by a novel synthetic compound SK 2009

  摘要：

  The NF-kappa B family of transcription factors plays an important role in determining cell survival during immune, inflammatory, and stress responses. NF-kappa B activity is frequently deregulated in human cancers and is implicated in the resistance of tumor cells to diverse anticancer agents. We studied the effects of novel analogs of precursors of the natural product simplactone (A) on the activity of IkB kinase and NF-kappa B. Screening of six compounds for the ability to inhibit TNF-induced NF-kappa B activity revealed that compound SK2009 was the most potent of these compounds in suppressing NF-kappa B activation in KBM-5 leukemic cells. Further characterization of SK2009 indicates that this newly synthesized molecule can suppress TNF-induced I kappa B alpha kinase activation and inhibit the expression of three NF-kappa B-dependent gene products, cyclin D1, Bcl-2, and VEGF, in these cells. Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmc.2009.10.065

文献信息

• Inhibition of IkB kinase and NF-κB by a novel synthetic compound SK 2009
  作者：Ravi Kumar Anchoori、Kuzhuvelil B. Harikumar、Venkateswara Rao Batchu、Bharat B. Aggarwal、Saeed R. Khan

  DOI：10.1016/j.bmc.2009.10.065

  日期：2010.1

  The NF-kappa B family of transcription factors plays an important role in determining cell survival during immune, inflammatory, and stress responses. NF-kappa B activity is frequently deregulated in human cancers and is implicated in the resistance of tumor cells to diverse anticancer agents. We studied the effects of novel analogs of precursors of the natural product simplactone (A) on the activity of IkB kinase and NF-kappa B. Screening of six compounds for the ability to inhibit TNF-induced NF-kappa B activity revealed that compound SK2009 was the most potent of these compounds in suppressing NF-kappa B activation in KBM-5 leukemic cells. Further characterization of SK2009 indicates that this newly synthesized molecule can suppress TNF-induced I kappa B alpha kinase activation and inhibit the expression of three NF-kappa B-dependent gene products, cyclin D1, Bcl-2, and VEGF, in these cells. Published by Elsevier Ltd.